Mesoblast Limited

162 articles with Mesoblast Limited

• Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions

  10/2/2018

  Mesoblast Limited today announced that the 159-patient randomized placebo-controlled Phase 2b trial evaluating its allogeneic mesenchymal precursor cell (MPC) product candidate MPC-150-IM in the treatment of end-stage heart failure patients implanted with a left ventricular assist device (LVAD) has been selected as a late-breaking presentation at the 2018 Scientific Sessions of the American Heart Association being held in Chicago from November 11-13.  

• 

  Who are the Top 3 Biotech Takeover Targets?

  5/22/2018

  Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.

• FDA Grants RMAT Designation For Mesoblast's Cell Therapy in Heart Failure Patients With LVADs

  12/21/2017

  The RMAT designation under the 21st Century Cures Act aims to expedite the development of regenerative medicine therapies intended for the treatment of serious diseases and life-threatening conditions.

• Mesoblast's Phase III Trial in Children With Acute Graft Versus Host Disease Completes Enrollment

  12/20/2017

  Top-line results are expected in Q1 2018. 

• Mesoblast Grants Tigenix an Exclusive Global Patent License to Use Adipose-Derived Mesenchymal Stem Cells in the Local Treatment of Fistulae

  12/15/2017

  The agreement includes the right for TiGenix to grant sub-licenses to affiliates and third parties, including TiGenix’s current development and commercialization partner ex-United States.

• Mesoblast Named Global Technology Leader in Cell Therapy Industry

  12/11/2017

  Mesoblast Limited has been named by Frost & Sullivan as the 2017 Global Technology Leader in the Cell Therapy Industry.

• Mesoblast’s US $40 Million Raise Oversubscribed As Its Pipeline Of Late-Phase Regenerative Drugs Continues To Progress

  9/28/2017

• Mesoblast And Mallinckrodt Enter Into Equity Purchase Agreement To Exclusively Negotiate Development And Commercialization Of Mesoblast's Cell Therapy Products For Chronic Low Back Pain And Acute Graft Versus Host Disease

  12/27/2016

• Mesoblast Plans to Reduce FY17 Cash Burn to Fund Clinical Operations and Phase III Heart Failure Trial

  7/1/2016

• Mesoblast Stock Sinks 42% After Teva Withdraws from Heart Failure Trials

  6/14/2016

• Mesoblast Provides Strategic Update And Reports On First Quarter Financial Results

  12/17/2015

• Mesoblast’s Japan Licensee Receives Pricing For TEMCELL HS Inj. For Treatment Of Acute Graft Versus Host Disease

  11/30/2015

• Mesoblast Lists On Nasdaq

  11/16/2015

• Mesoblast Announces Pricing Of Public Offering On Nasdaq

  11/13/2015

• Mesoblast Release: Key United States Patent Granted For The Treatment Of Heart Diseases, Stroke And Other Vascular Conditions

  10/28/2015

• Mesoblast Chairman's Address To 2015 Annual General Meeting

  10/22/2015

• Celgene And Mesoblast Extend Agreement

  10/16/2015

• Phase II Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure

  9/30/2015

• Full Product Approval In Japan Received By Mesoblast Licensee

  9/18/2015

• Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan

  9/4/2015